Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 6, 2013, Pages 559-570

  Varas Lorenzo, Cristina ^a   Riera Guardia, Nuria ^a   Calingaert, Brian ^a   Castellsague, Jordi ^a   Salvo, Francesco ^b   Nicotra, Federica ^c   Sturkenboom, Miriam ^d   Perez Gutthann, Susana ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anti inflammatory agents; Epidemiology; Meta analysis; Myocardial infarction; Non steroidal; Observational studies; Pharmacoepidemiology

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; DICLOFENAC; ETODOLAC; ETORICOXIB; IBUPROFEN; INDOMETACIN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; ROFECOXIB;

ACUTE HEART INFARCTION; CARDIOVASCULAR RISK; DOSE RESPONSE; DRUG SAFETY; HIGH RISK POPULATION; HUMAN; META ANALYSIS; OBSERVATIONAL STUDY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; META-ANALYSIS AS TOPIC; MYOCARDIAL INFARCTION; OBSERVATIONAL STUDY AS TOPIC; PHARMACOEPIDEMIOLOGY; RISK;

EID: 84878800652     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3437     Document Type: Review

References (49)

1. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8, 2 p following 8. DOI:10.1056/NEJM200011233432103.
2. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-102. DOI:10.1056/NEJMoa050493.
3. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-80. DOI:10.1056/NEJMoa050405
4. Hernández-Díaz S, Varas-Lorenzo C, García Rodríguez LA. Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 2006; 98: 266-74. DOI:10.1111/j.1742-7843.2006.pto_302.x
5. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302-8. DOI:10.1136/bmj.332.7553.1302
6. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296: 1633-44. DOI:10.1001/jama.296.13.jrv60011
7. Scott PA, Kingsley GH, Smith CM, Choy EH, Scott DL. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis 2007; 66: 1296-304. DOI:10.1136/ard.2006.068650.
8. Capone ML, Tacconelli S, Rodriguez LG, Patrignani P. NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. Pharmacol Rep 2010; 62: 530-5.
9. Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 2004; 109: 1468-71. DOI:10.1161/01.CIR.0000124715.27937.78
10. Wells GA, Shea B, O'Connel lD, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa, Ontario: Ottawa Health Research Institute; 2010. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. (accessed 9 November 2011).
11. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88. DOI:0197-2456(86)90046-2.
12. Abraham NS, El-Serag HB, Hartman C, Richardson P, Deswal A. Cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction and cerebrovascular accident. Aliment Pharmacol Ther 2007; 25: 913-24. DOI:10.1111/j.1365-2036.2007.03292.x.
13. Solomon DH, Avorn J, Stürmer T, Glynn RJ, Mogun H, Schneeweiss S. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum 2006; 54: 1378-89. DOI:10.1002/art.21887.
14. Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-3. DOI:10.1016/S0140-6736(02)11131-7
15. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365: 475-81. DOI:10.1016/S0140-6736(05)17864-7
16. Kimmel SE, Berlin JA, Reilly M, et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005; 142: 157-64.
17. Varas-Lorenzo C, Castellsague J, Stang MR, Perez-Gutthann S, Aguado J, Rodriguez LA. The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada. Pharmacoepidemiol Drug Saf 2009; 18: 1016-25. DOI:10.1002/pds.1815
18. Lévesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005; 142: 481-9.
19. Mamdani M, Rochon P, Juurlink DN, et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 2003; 163: 481-6. DOI:ioi20571.
20. McGettigan P, Han P, Henry D. Cyclooxygenase-2 inhibitors and coronary occlusion--exploring dose-response relationships. Br J Clin Pharmacol 2006; 62: 358-65. DOI:10.1111/j.1365-2125.2006.02660.x.
21. Andersohn F, Suissa S, Garbe E. Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs and risk of acute myocardial infarction. Circulation 2006; 113: 1950-7. DOI:10.1161/CIRCULATIONAHA.105.602425
22. García Rodríguez LA, Tacconelli S, Patrignani P. Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. J Am Coll Cardiol 2008; 52: 1628-36.
23. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005; 330: 1366. DOI:10.1136/bmj.330.7504.1366
24. Fosbøl EL, Folke F, Jacobsen S, et al. Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals. Circ Cardiovasc Qual Outcomes 2010; 3: 395-405. DOI:10.1161/circoutcomes.109.861104
25. Helin-Salmivaara A, Virtanen A, Vesalainen R, et al. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur Heart J 2006; 27: 1657-63. DOI:10.1093/eurheartj/ehl053
26. Van der Linden MW, Van der Bij S, Welsing P, Kuipers EJ, Herings RM. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non steroidal anti-inflammatory drugs. Ann Rheum Dis 2008; 68: 668-73. DOI:10.1136/ard.2007.087254.
27. Johnsen SP, Larsson H, Tarone RE, et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Arch Intern Med 2005; 165: 978-84. DOI:10.1001/archinte.165.9.978
28. Bueno H, Bardají A, Patrignani P, Martín-Merino E, García-Rodríguez LA. Use of non-steroidal antiinflammatory drugs and type-specific risk of acute coronary syndrome. Am J Cardiol 2010; 105: 1102-6. DOI:10.1016/j.amjcard.2009.12.008
29. Ray WA, Varas-Lorenzo C, Chung CP, et al. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease. Circ Cardiovasc Qual Outcomes 2009; 2: 155-63. DOI:10.1161/circoutcomes.108.805689
30. Solomon DH, Glynn RJ, Levin R, Avorn J. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002; 162: 1099-104.
31. Lévesque LE, Brophy JM, Zhang B. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors. CMAJ 2006; 174: 1563-9. DOI:10.1503/cmaj.051679
32. Brophy JM, Lévesque LE, Zhang B. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart 2007; 93: 189-94. DOI:10.1136/hrt.2006.089367.
33. García Rodríguez LA, Varas-Lorenzo C, Maguire A, González-Pérez A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004; 109: 3000-6. DOI:10.1161/01.CIR.0000132491.96623.04.
34. García Rodríguez LA, González-Pérez A. Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med 2005; 3: 17. DOI:10.1186/1741-7015-3-17.
35. Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation 2011; 123: 2226-35. DOI:10.1161/CIRCULATIONAHA.110.004671
36. Gislason GH, Jacobsen S, Rasmussen JN, et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006; 113: 2906-13. DOI:10.1161/CIRCULATIONAHA.106.616219.
37. The Cochrane Collaboration. Publication bias: interpreting funnel plots. The Cochrane Collaboration open learning material. 2002. Available at: http://www.cochrane-net.org/openlearning/html/mod15-3.htm. (accessed 4 May 2012).
38. Salvo F, Fourrier-Reglat A, Bazin F, et al. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther 2011; 89: 855-66. DOI:10.1038/clpt.2011.45.
39. McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med 2011; 8: e1001098. DOI:10.1371/journal.pmed.1001098.
40. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Stroke risk and NSAIDs: a systematic review of observational studies. Pharmacoepidemiol Drug Saf 2011; 20: 1225-36. DOI:10.1002/pds.2227
41. Hammad TA, Graham DJ, Staffa JA, Kornegay CJ, Dal Pan GJ. Onset of acute myocardial infarction after use of non-steroidal anti-inflammatory drugs. Pharmacoepidemiol Drug Saf 2008; 17: 315-21. DOI:10.1002/pds.1560.
42. Kimmel SE, Berlin JA, Reilly M, et al. The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol 2004; 43: 985-90. DOI:10.1016/j.jacc.2003.08.064
43. Adabag AS, Peterson G, Apple FS, Titus J, King R, Luepker RV. Etiology of sudden death in the community: results of anatomical, metabolic, and genetic evaluation. Am Heart J 2010; 159: 33-9. DOI:10.1016/j.ahj.2009.10.019
44. Dudas K, Lappas G, Stewart S, Rosengren A. Trends in out-of-hospital deaths due to coronary heart disease in Sweden (1991 to 2006). Circulation 2011; 123: 46-52. DOI:10.1161/CIRCULATIONAHA.110.964999
45. Horwitz RI, Feinstein AR. Exclusion bias and the false relationship of reserpine and breast cancer. Arch Intern Med 1985; 145: 1873-5.
46. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003; 158: 915-20.
47. Suissa S, Garbe E. Primer: administrative health databases in observational studies of drug effects--advantages and disadvantages. Nat Clin Pract Rheumatol 2007; 3: 725-32. DOI:10.1038/ncprheum0652.
48. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167: 492-9. DOI:10.1093/aje/kwm324
49. Greenland S. Introduction to regression models. Lippincott-Raven: Hagerstown (MD), 1998.